Viewing Study NCT03580369


Ignite Creation Date: 2025-12-24 @ 11:03 PM
Ignite Modification Date: 2025-12-25 @ 8:34 PM
Study NCT ID: NCT03580369
Status: COMPLETED
Last Update Posted: 2023-07-24
First Post: 2018-06-26
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Sponsor: Novartis Pharmaceuticals
Organization: